Treating Africa: The use of less than fully tested drugs to treat Ebola can be justified...

But medicine is not the only answer here

Share

Desperate times call for desperate measures, and the situation in West Africa unquestionably deserves to be put in that category. So far, more than 1,000 people have died as a result of the worst known outbreak of the Ebola virus. In response, the World Health Organisation (WHO) took the unprecedented step this week of announcing that experimental drugs and treatments, “with as-yet-unknown efficacy and side effects”, could be used on patients who have contracted the disease. A panel of medical experts in Geneva concluded that, with victims facing a 70 or 80 per cent mortality rate, the Hippocratic oath to “do no harm” was insufficient reason to prevent desperate men and women from taking advantage of risky but potentially life-saving medicines.

Their decision to overrule the central principles of Western drug safety – that nothing can be used on humans without a process of trials often lasting more than a decade – was clearly not taken lightly. Nor should the layman object to it in principle. Put crudely, when your other option is a likely death, there’s little to be lost in submitting to a regimen that medical researchers at least tentatively believe may do some good.

Nevertheless, the introduction of a small supply of drugs and vaccines into a situation as precarious as that in Western Africa, where several nations have already announced states of emergency, brings its own questions. There was uproar when two US aid workers who contracted the virus in Liberia were flown back to America and dosed with ZMapp, an experimental treatment never before taken by humans. Why did they receive special treatment when the overwhelming majority of the victims are African men and women?

There is a reasonable answer to that, at least in the short term: the drug was produced with the help of funds from the US Department of Defence, so it is to be expected that the first patients to use it fall within the citizenry of the United States. Furthermore, had the medication been a disastrous failure – using it first on, say, Liberian men and women – there would likely have been the accusation that this was a case of a rich nation being prepared to treat men and women from a poor one as human guinea pigs.

In the longer term, however, the inequalities behind the spread of this disease are glaring. That no vaccine or cure has so far been brought to market is related to its status as an African problem. More money goes into fighting baldness and erectile dysfunction than haemorrhagic fevers of the sort that rarely spread into the developed world. Private companies, which provide the majority of research funding, have little interest in ploughing funds into a disease that primarily affects poor communities. Many will recall the attempt by Western pharmaceutical companies to prevent Indian firms from producing a generic version of their antiretroviral treatments at the turn of this century, thereby putting profit above the lives of millions of African sufferers of Aids.

Today’s announcement that Canada will donate 1,000 doses of an experimental vaccine to the WHO further ramped up hopes of a medical solution to this crisis. In truth, the best way to ease the epidemic will not be found in Western laboratories: the quantities of available drugs are too small at this stage, and the pipeline too slow, even if safety regulations have been brushed aside. Better to concentrate on what can be done in the here and now: that is, isolate known patients, trace their contacts, and inform communities about how Ebola travels from person to person. A silver bullet will not take down the virus. Logistics have the ability to save many more lives.

React Now

Latest stories from i100
iJobs Job Widget
iJobs General

Tradewind Recruitment: English Teacher

Negotiable: Tradewind Recruitment: This post arises as a result of the need to...

Tradewind Recruitment: Class Teacher Required ASAP In Uminster

£120 - £150 per annum: Tradewind Recruitment: I am recruiting on instruction o...

Ashdown Group: Head of Finance - Financial Director - London - £70,000

£70000 per annum: Ashdown Group: Head of Finance - Financial Controller - Fina...

Ashdown Group: Marketing Executive - Wimbledon, SW London

£24000 - £28000 per annum + benefits: Ashdown Group: Marketing Executive - Wim...

Day In a Page

Read Next
 

I’m not sure I fancy any meal that’s been cooked up by a computer

John Walsh
Labour leader Ed Miliband delivers a speech on his party's plans for the NHS, in Sale, on Tuesday  

Why is Miliband fixating on the NHS when he’d be better off focussing on the wealth gap?

Andreas Whittam Smith
Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

Isis stands strong as its numerous enemies fail to find a common plan to defeat it

The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

Virtual reality: Seeing is believing

Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
Homeless Veterans appeal: MP says Coalition ‘not doing enough’

Homeless Veterans appeal

MP says Coalition ‘not doing enough’ to help
Larry David, Steve Coogan and other comedians share stories of depression in new documentary

Comedians share stories of depression

The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
Has The Archers lost the plot with it's spicy storylines?

Has The Archers lost the plot?

A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
English Heritage adds 14 post-war office buildings to its protected lists

14 office buildings added to protected lists

Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Scientists unearthed the cranial fragments from Manot Cave in West Galilee
World War Z author Max Brooks honours WW1's Harlem Hellfighters in new graphic novel

Max Brooks honours Harlem Hellfighters

The author talks about race, legacy and his Will Smith film option to Tim Walker
Why the league system no longer measures up

League system no longer measures up

Jon Coles, former head of standards at the Department of Education, used to be in charge of school performance rankings. He explains how he would reform the system
Valentine's Day cards: 5 best online card shops

Don't leave it to the petrol station: The best online card shops for Valentine's Day

Can't find a card you like on the high street? Try one of these sites for individual, personalised options, whatever your taste
Diego Costa: Devil in blue who upsets defences is a reminder of what Liverpool have lost

Devil in blue Costa is a reminder of what Liverpool have lost

The Reds are desperately missing Luis Suarez, says Ian Herbert
Ashley Giles: 'I'll watch England – but not as a fan'

Ashley Giles: 'I'll watch England – but not as a fan'

Former one-day coach says he will ‘observe’ their World Cup games – but ‘won’t be jumping up and down’
Greece elections: In times like these, the EU has far more dangerous adversaries than Syriza

Greece elections

In times like these, the EU has far more dangerous adversaries than Syriza, says Patrick Cockburn
Holocaust Memorial Day: Nazi victims remembered as spectre of prejudice reappears

Holocaust Memorial Day

Nazi victims remembered as spectre of prejudice reappears over Europe
Fortitude and the Arctic attraction: Our fascination with the last great wilderness

Magnetic north

The Arctic has always exerted a pull, from Greek myth to new thriller Fortitude. Gerard Gilbert considers what's behind our fascination with the last great wilderness